HLA-B*5701 screening significantly reduces the risk of an ABC hypersensitivity reaction (HSR)
Prospective HLA-B*5701 screening: No immunologically confirmed HSR and significant reduction of clinically suspected HSR in the PREDICT-1 study
Clinical description of HSRs:
- Almost all patients developing hypersensitivity reactions will have fever and/or rash (usually maculopapular or urticarial) as part of the syndrome, however reactions have occurred without rash or fever. Other key symptoms include gastrointestinal, respiratory or constitutional symptoms such as lethargy and malaise.
- Other key symptoms include: gastrointestinal, respiratory or constitutional symptoms such as lethargy and malaise
- TRIUMEQ must be stopped without delay, even In the absence of the HLA-B*5701 allele
- After stopping treatment with TRIUMEQ for a suspected HSR, TRIUMEQ or any other medicinal product containing ABC or Dolutegravir, must never be re-initiated
- EACS and DHHS guidelines recommend screening for HLA-B*5701 before starting ABC-containing antiretroviral therapy, if not previously tested.
- Mallal S, Phillips E, Carosi G, et al; for the PREDICT-1 Study Team. HLA-B*5701 screening for hypersensitivity to Abacavir. N Engl J Med. 2008;358:568-579.TRIUMEQ Summary of Product Characteristics.
- TRIUMEQ Summary of Product Characteristics.
- European AIDS Clinical Society. Guidelines. Version 8.1. October 2016. http://www.eacsociety.org/files/guidelines_8.1-english.pdf . Accessed Dec, 2016.
- Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Department of Health and Human Services. July 14, 2016. https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. Accessed May 1, 2016.